Total Funding
64
58
Total FundingSeries B raised
Growth Score
-2 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
38036
EXUMA Biotech is a clinical-stage biotechnology company that focuses on discovering and developing CAR-T cell products for solid tumors.
- James Samuels: Chief Financial OfficerPast Role: Vetsource, CFO
- Gregory Frost: Chairman & CEOPast Role: Precigen, SVP Health Sector
About the Company
EXUMA Biotech is a clinical-stage biotechnology company discovering and developing Chimeric Antigen Receptor (CAR)-T cell products for solid tumors. They develop new tools for the patient’s immune system to fight various solid tumor malignancies, such as renal cell carcinoma, soft tissue sarcoma, gastric cancer, and others.
It was founded in 2015
and headquartered in Grand Cayman, Midland.
